Subscribe Now Subscribe Today
Science Alert
 
FOLLOW US:     Facebook     Twitter
Blue
   
Curve Top
American Journal of Drug Discovery and Development
  Year: 2017 | Volume: 7 | Issue: 1 | Page No.: 48-53
DOI: 10.3923/ajdd.2017.48.53
Two-week Treatment with Diuretics as Add on Therapy is Enough to Control the Blood Pressure in Patients Presented with Uncontrolled-resistant Hypertension
Marwan Salih Mohamud Al-Nimer and Rozhgar Faisal Ahmed

Abstract:
Background and Aim: Diuretics used as a first line therapy in the management of hypertension. Spironolactone is the fourth drug that indicated in the management of resistant hypertension. This study aimed to clarify the importance of using short term therapy for 2 weeks as add on therapy in the management of uncontrolled-resistant hypertension. Materials and Methods: A total number of 120 patients were enrolled in open label clinical study. The patients are assigned to receive 2 week therapy of a single daily dose of amiloride (5 mg) plus hydrochlorothiazide (50 mg) (Group I), or 50 mg spironolactone (Group II) or 50 mg hydrochlorothiazide (Group III). The following measurements, including the anthropometric measurement, blood pressure, lipid profile and serum electrolytes were considered. Results: Diuretics produced significant reduction of the blood pressure of systolic and diastolic that amounted 23 and 14.2% (Group I), 24.3 and 14.4% (Group II) and 25.4 and 13.0% (Group III) of the baseline value. They induced alterations in serum electrolytes in Group II and III. Conclusion: Two- week therapeutic regimens of diuretics are enough to achieve the control of blood pressure and the logic drug for resistant hypertension is spironolactone.
 [Fulltext PDF]   [Fulltext HTML]   [XML: Abstract + References]   [References]   [View Citation]  [Report Citation]
How to cite this article:

Marwan Salih Mohamud Al-Nimer and Rozhgar Faisal Ahmed, 2017. Two-week Treatment with Diuretics as Add on Therapy is Enough to Control the Blood Pressure in Patients Presented with Uncontrolled-resistant Hypertension. American Journal of Drug Discovery and Development, 7: 48-53.

DOI: 10.3923/ajdd.2017.48.53

URL: https://scialert.net/abstract/?doi=ajdd.2017.48.53

 
COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 

Curve Bottom